Gilead reported Phase 2 results for emvistegrast, an oral therapy targeting inflammatory bowel disease, showing a statistically significant improvement in clinical remission for moderate-to-severe ulcerative colitis. In the 12-week study, a 200 mg daily dose produced a 23% placebo-adjusted remission rate, exceeding Wall Street expectations. The company framed the data as potential positioning for a best-in-class oral option for a population where many patients still do not reach remission on existing therapies. Gilead is now advancing the program to support its broader pipeline in inflammatory and autoimmune indications. The update matters for treatment strategy because oral agents can change adherence dynamics, safety management, and sequencing versus infusion- or injection-based biologics and small molecules—particularly in mid-stage patients who need symptom control while clinicians attempt longer-term disease modification.